A multicentre randomised phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma
PROMISE-meso: Pembrolizumab immunotherapy versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma
Systemic chemotherapy is currently the international standard care of treatment for patients with advanced pleural mesothelioma, where surgery is not possible. However, the median survival for these patients is only 9-12 month and there is unmet need for an effective therapy for patients with relapsed pleural mesothelioma.
Pembrolizumab is a potent and highly selective antibody, designed to directly block the interaction between PD-1 and its ligands.
The aim of the PROMISE-meso trial was to investigate whether treatment with pembrolizumab improves progression-free survival (PFS) compared to standard chemotherapy (gemcitabine or vinorelbine).
Trial Scheme
